Reviparin sodium: Difference between revisions
(Created page with " {{Drugbox | Verifiedfields = changed | verifiedrevid = 447910442 | IUPAC_name = | image = <!--Clinical data--> | tradename = | Drugs.com = {{drugs.com|international|revi...") |
No edit summary |
||
| Line 43: | Line 43: | ||
| molecular_weight = | | molecular_weight = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Reviparin''' is an antithrombotic and belongs to the group of [[low molecular weight heparin]]s. | '''Reviparin''' is an antithrombotic and belongs to the group of [[low molecular weight heparin]]s. | ||
| Line 55: | Line 59: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist|2}} | ||
==External links== | ==External links== | ||
| Line 63: | Line 67: | ||
{{Antithrombotics}} | {{Antithrombotics}} | ||
[[Category: | [[Category:Drug]] | ||
Revision as of 18:33, 15 April 2015
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
  (what is this?) (verify) | |
|
WikiDoc Resources for Reviparin sodium |
|
Articles |
|---|
|
Most recent articles on Reviparin sodium Most cited articles on Reviparin sodium |
|
Media |
|
Powerpoint slides on Reviparin sodium |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Reviparin sodium at Clinical Trials.gov Trial results on Reviparin sodium Clinical Trials on Reviparin sodium at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Reviparin sodium NICE Guidance on Reviparin sodium
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Reviparin sodium Discussion groups on Reviparin sodium Patient Handouts on Reviparin sodium Directions to Hospitals Treating Reviparin sodium Risk calculators and risk factors for Reviparin sodium
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Reviparin sodium |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins.
Pharmacodynamic
Reviparin is a low molecular weight heparin (LMWH) obtained by nitrous acid depolymerization of heparin extracted from porcine intestinal mucosa. Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular weight is about 3900 daltons.
Indications
- Prophylaxis of deep vein thrombosis (DVT)
- Prophylaxis of perioperative thromboembolism[1][2]
- Treatment of DVT with or without pulmonary embolism (PE)[3]
- Prophylaxis of acute thrombotic events after percutaneous transluminal coronary angioplasty (PTCA)[4][5]
References
- ↑ Kakkar VV, Cohen AT, Mohamed MS (1996). "Patients at risk of venous thromboembolism--clinical results with reviparin". Thromb. Res. 81 (2 Suppl): S39–45. PMID 8822126.
|access-date=requires|url=(help) - ↑ Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, Coff-Ganes H, Jeppesen E (1999). "Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery". Semin. Thromb. Hemost. 25 Suppl 3: 79–82. PMID 10549720.
|access-date=requires|url=(help) - ↑ Gore M, Kelkar P, Rege N, Ross C (October 2004). "Reviparin sodium clivarine: a review of its therapeutic use". J Indian Med Assoc. 102 (10): 589–90, 592. PMID 15887830.
|access-date=requires|url=(help) - ↑ Preisack MB, Karsch KR (December 1993). "Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty". Blood Coagul. Fibrinolysis. 4 Suppl 1: S55–8, discussion S59–60. PMID 8180331.
|access-date=requires|url=(help) - ↑ Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (November 1996). "Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation". J. Am. Coll. Cardiol. 28 (6): 1437–43. doi:10.1016/s0735-1097(96)00343-9. PMID 8917255. Retrieved 2014-09-18.
External links
- reviparin at the US National Library of Medicine Medical Subject Headings (MeSH)
- Yusuf S, Mehta SR, Xie C; et al. (2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation". JAMA. 293 (4): 427–35. doi:10.1001/jama.293.4.427. PMID 15671427.
- Pages with script errors
- Pages using citations with accessdate and no URL
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Articles with changed ChemSpider identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Infobox drug tracked parameters
- CS1 maint: Explicit use of et al.
- Drug